Carol Werther

CRT Capital on Wednesday initiated coverage on Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) after the company has made strides toward commercializing its products. CRT Capital rates Ultragenyx as a Buy with a $90 price target. Analyst Carol Werther wrote, "Six programs are in Phases 2 or 3 of the...

Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) responded following an early Friday formal announcement that the company has U.S. approval to bring Inclusig back to the market, and will begin to sell by mid- January. Ariad shares hit $7.75, up 40 percent. Ariad said, "The USPI includes a revised...

Avanir Pharmeceuticals (NASDAQ: AVNR) stock plummeted yesterday after Gravity Research said Avanir, “engaged in illegal off-label marketing of Nuedexta,” and recommended a strong Sell. Shares closed at $4.79 on Wednesday, a 13 percent decrease. This was the biggest drop of AVNR in three years...